Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range

Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range


Waystar CEO: We're building a visible, recurring revenue business driving profitable growth

Waystar shares slid about 3% in their Nasdaq debut on Friday, after the health-care payment software vendor priced its IPO in the middle of the expected range.

The stock opened at $21 per share, below the IPO price of $21.50 late Thursday. Waystar said its expected price would be between $20 and $23 per share in May. Shares closed down more than 3% to $20.70 on Friday.

The IPO market has been largely dormant since late 2021 when the extended bull market turned and investors began to worry about a weakening economy. Few technology companies have been willing to try and go public since then, and no digital health companies had a public exit in 2023, according to a report from Rock Health.

But the broader venture-backed tech market may be beginning to thaw. Social media platform Reddit, data center connectivity chip vendor Astera Labs and data software management maker Rubrik have all gone public this year. Health tech company Tempus AI has also issued a preliminary prospectus this year.

Based on Waystar’s initial share price, the company’s market cap is about $3.5 billion. The stock is trading under the ticker symbol “WAY.”

Waystar offers health-care payment and revenue cycle management tools and facilitates more than 5 billion payment transactions annually, according to its prospectus. The company was formed in 2017 after the health-care payment companies Navicure and ZirMed merged.

“We’re excited about the opportunity to be a public company because we think it helps us with awareness, helps us with credibility, helps us improve our capital structure and allows for further investments in areas such as generative AI,” Waystar CEO Matt Hawkins told CNBC’s “The Exchange” Friday.

For the quarter ending March 31, Waystar generated revenue of $224.8 million, up 18% from $191.1 million in the same period last year. Waystar reported a net loss of $15.9 million for the quarter compared with $10.6 million a year ago.

The company said it plans to use the money from the offering to pay off existing debt. JPMorgan Chase, Goldman Sachs and Barclays are leading the offering.

WATCH: Tech IPOs face hurdle

Startup valuations' impact on IPOs



Source

Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
Health

Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk

US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. 6, 2025. Andrew Caballero-Reynolds | AFP | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in how many people can access […]

Read More
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 
Health

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]

Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Health

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]

Read More